Vectus Biosystems (ASX:VBS)
ASX announcement history & article coverage
Transparent by design.
Announcments by Vectus Biosystems (ASX:VBS) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
FDA Pre-IND Meeting Request Granted for VB0004
Vectus receives FDA pre-IND meeting approval for VB0004 IPF program
2026 Notice of Annual General Meeting & Proxy Form
2026 Corporate Governance Statement & Appendix 4G
Annual Report to shareholders
Vectus reports FY2026 profit after XORTX asset transaction while advancing VB0004 and managing funding risk
Date of 2026 Annual General Meeting
Change of Director's Interest Notice - MS
Cleansing Notice
Application for quotation of securities - VBS
Full Year Statutory Accounts
Preliminary Final Report
Vectus Biosystems posts AUD 1.56 million profit for FY2026, reversing prior year loss
Cleansing Notice
Application for quotation of securities - VBS
Quarterly Activities & Appendix 4C Cash Flow Reports
Vectus Biosystems appoints new CEO, raises $0.79M, sells renal compound, and engages US regulatory agent